The global digital therapeutics market is projected to grow from USD 10.95 billion in 2026 to USD 35.37 billion by 2031, representing a 26.4% compound annual growth rate, according to a ResearchAndMarkets.com report. Expansion is being driven by chronic disease prevalence, demand for personalized and remote care, pressure to improve clinical outcomes and reduce costs, and wider use of artificial intelligence, remote monitoring, wearables and interoperable digital-health infrastructure. Hospitals held the largest end-user share in 2025, while the business-to-consumer channel is forecast to record the fastest growth through 2031. Asia Pacific is expected to post the highest regional growth rate. The report covers software and platforms, therapeutic programs, immersive and interface-based therapeutics, applications, revenue models, sales channels, end users and five global regions. Reimbursement fragmentation, regulatory complexity, privacy and cybersecurity concerns, limited awareness and the need for long-term clinical and economic evidence remain key constraints.